Skip to main navigation
Go to NovaBridge Biosciences homepage
  • Home
  • About
    • Who We Are
    • Leadership Team
    • Careers
  • Innovation
    • Science
    • Publications & Presentations
  • Pipeline
    • Pipeline
    • Clinical Trials
    • Expanded Access Policy
    • Externally Sponsored Research
  • News & Events
    • News
    • Events
  • Investors
    • Overview
    • Corporate
      • Corporate Profile
      • Corporate Governance
    • News & Events
      • News Releases
      • Event Calendar
      • Presentations & Webcasts
    • Stock
      • Stock Quote & Chart
      • Historical Lookup
      • Analyst Coverage
    • Financials
      • SEC Filings
      • Annual Reports
    • ESG
    • IR Resources
      • Investor FAQs
      • Email Alerts
      • Contact
  • search icon
Go to NovaBridge Biosciences homepage
  • Home
  • About
    • Who We Are
    • Leadership Team
    • Careers
  • Innovation
    • Science
    • Publications & Presentations
  • Pipeline
    • Pipeline
    • Clinical Trials
    • Expanded Access Policy
    • Externally Sponsored Research
  • News & Events
    • News
    • Events
  • Investors
    • Overview
    • Corporate
      • Corporate Profile
      • Corporate Governance
    • News & Events
      • News Releases
      • Event Calendar
      • Presentations & Webcasts
    • Stock
      • Stock Quote & Chart
      • Historical Lookup
      • Analyst Coverage
    • Financials
      • SEC Filings
      • Annual Reports
    • ESG
    • IR Resources
      • Investor FAQs
      • Email Alerts
      • Contact

We are a global biotechnology platform company committed to accelerating access to innovative medicines.

Bridging Innovation to Health

Find out more

Pipeline

  • Givastomig

    Claudin 18.2 x 4-1BB bispecific antibody  

  • VIS-101

    VEGF-A / ANG2

  • Ragistomig

    PD-L1 x 4-1BB bispecific antibody  

  • Uliledlimab

    CD73 antibody  

Latest News

Press Releases

2026.03.16
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer
2026.03.09
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
View All News Releases

Events

 
 
Mar 11, 2026 8:00 AM EDT

Leerink Partners 2026 Global Healthcare Conference

Mar 9, 2026 9:00 AM EDT

Novabridge & Visara Phase 2a Results of VIS-101

Jan 2, 2026 9:30 AM EST

Nasdaq Bell Ceremony

View All Events

Sitemap

  • Home
  • About
  • Innovation
  • Pipeline
  • News & Events
  • Investors
  • Careers
  • Contact

Follow Us

  • LinkedIn

Copyright © 2026 NovaBridge Biosciences. All Rights Reserved.

  • Terms of Use
  • Privacy Policy